EuroNeoNet (ENN) is a specialised neonatal network to provide networking to European neonatologists and other stakeholders a tool to perform quality assurance and benchmarking, and a framework to facilitate the development of high-quality outcome epidemiological research, implement quality improvement initiatives and randomised clinical trials. ENN is affiliated to the European Society for Paediatric Research and the European Society for Neonatology (ESPR/ESN).

The ENN Mission is to enhance neonatal networking to help neonatologist to promote a culture for quality of care improvements and patient safety, family-cantered and developmental care and dissemination of evidence-based interventions, e-learning, and to effectively conduct academically-driven clinical trials, case-control, cohort, cluster and nested studies.

Our Vision statement s ithat all Very Low-Gestational Age (VLGA, <32 weeks) and Very-Low-Birth-Weight (VLBW, <1500 g) newborn infants born in Europe, receive the best possible health care no matter where born, by preventing any existing inequalities and that all Neonatal Units shear a standardised perinatal risk and protective factors, neonatal interventions and short- and long-term outcomes for those tinny and vulnerable infants.

Our organization values are guided by the democratic, transparency, equal opportunity, values common to the European culture, and to shear all information gathered to help any interested stakeholders.

Our strategic aim is to consolidate a standardised set of health indicators to assess the quality of health care delivered to very premature infants by European institutions, regions and countries. We aim to reduce neonatal morbidity and mortality and improve their health status at 2 years, detect any inequalities that might exist.

Communication to the key interested stakeholders is mainly performed via our interactive website (www.euroneonet.org), but periodic report, newsletters, leaflets, publications, abstracts and presentations are also periodically and widely disseminated.




EuroNeoNet (ENN) is a specialized neonatal network to provide networking to European neonatologists and other stakeholders a tool to perform quality assurance and benchmarking, and a framework to facilitate the development of high-quality outcome epidemiological research, implement quality improvement initiatives and randomized clinical trials. ENN is affiliated to the European Society for Paediatric Research and the European Society for Neonatology (ESPR/ESN).

The ENN Mission is to enhance neonatal networking to help neonatologist to promote a culture for quality of care improvements and patient safety, family-centered and developmental care and dissemination of evidence-based interventions, e-learning, and to effectively conduct academically-driven clinical trials, case-control, cohort, cluster and nested studies.

Our Vision statement is that all Very Low-Gestational Age (VLGA, <32 weeks) and Very-Low-Birth-Weight (VLBW, <1500 g) newborn infants born in Europe, receive the best possible health care no matter where born, by preventing any existing inequalities and that all Neonatal Units shear a standardized perinatal risk and protective factors, neonatal interventions and short- and long-term outcomes for those tinny and vulnerable infants.

Our organization values are guided by the democratic, transparency, equal opportunity, values common to the European culture, and to shear all information gathered to help any interested stakeholders.

Our strategic aim is to consolidate a standardized set of health indicators to assess the quality of health care delivered to very premature infants by European institutions, regions and countries. We aim to reduce neonatal morbidity and mortality and improve their health status at 2 years, detect any inequalities that might exist.

Communication to the key interested stakeholders is mainly performed via our interactive website (www.euroneonet.org), but periodic reports, newsletters, leaflets, publications, abstracts and presentations are also periodically and widely disseminated.




WP4 mobilises MS to carry out alcohol surveys using a common methodology and to pool data for comparative assessment in order to produce a baseline for comparative monitoring of drinking levels and patterns and alcohol related harms across the EU. The ultimate objective is to provide methodological and policy pointers and increase interest in carrying out common surveys in the future.

WP5 combines scientific knowledge on risks and experiences of the use of drinking guidelines to clarify their scientific basis and practical implications and to work towards consensus on good practice principles for the use of drinking guidelines as a public health measure. The ultimate objective is to contribute towards more aligned messages to the population and health professionals.

WP6 produces a Tool Kit of likey transferable interventions on which some evidence of effectiveness and cost estimates are available. The ultimate objective is to facilitate exchange between MS public health bodies and provide guidance for the use of evidence based approaches to reduce alcohol related harm.



The project will support improved treatment and standards of care patients who undergo cataract and refractive surgeries in Europe. This will be achieved through the development of a Europe-wide network (EUREQUO) of national registries reporting clinical outcomes in the field of cataract and refractive surgeries. The project aims to make a significant impact on the exchange of good practice between practitioners in relation to patient safety in this field.


The general objective of BENCH-CAN is to benchmark comprehensive cancer care & yield best practice examples in a way that contributes to improving the quality of interdisciplinary patient treatment. To achieve this, the project addresses 6 specific objectives:

1. To collect, compare and align by consensus formation the standards, recommendations and accreditation criteria of comprehensive cancer care in selected European countries.
2. To review and refine a benchmarking tool that can be applied to comprehensive cancer care through interdisciplinary patient treatment.
3. To pilot the benchmark tool with particular attention to operations management and best clinical practice.
4. To maximise knowledge exchange and sharing of best practice between providers of comprehensive cancer care in member states and regions.
5. To ensure compatibility of the benchmarking tools with existing cancer care resources and services.
6. To ensure the sustainability and longer-term benefits of the project.

